ALEXANDRIA, Va. – Findings on combination therapies with immunotherapy drugs for patients with biliary tract cancer and hepatocellular carcinoma will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 650 abstracts that will be presented at the Symposium.
The 2022 ASCO Gastrointestinal Cancers Symposium, taking place January 20-22 in San Francisco, California, and online, will bring together oncology professionals from around the globe for presentations and discussions surrounding practice-changing findings in gastrointestinal cancer treatment, research, and care.
Abstracts will be publicly released on ASCO’s Meeting Experience on Tuesday, January 18, at 5:00 p.m. ET and the embargo will lift at that time. The following abstracts will be highlighted in press releases as a part of the Press Program:
- A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. (Abstract 378)
- A phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (Abstract 379)
Apply for/renew ASCO media credentials: Reporters with valid ASCO media credentials will be able to access embargoed press materials and view online presentations from the 2022 ASCO Gastrointestinal Cancers Symposium. Please visit ASCO’s Media Headquarters at mediahq.asco.org to request credentials or to ensure your credentials are up to date.
Attend the Symposium in Person: Credentialed media who would like to attend the meeting in person can contact Rachel Cagan at firstname.lastname@example.org to register. All in-person attendees must be fully vaccinated against COVID-19. Visit our Health and Safety page for more details.
Founded in 1964, the American Society of Clinical Oncology, Inc. (the Society) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO® represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality and equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.